Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (341-350 of 392) with videos related to

Pageof 40
Sort By:
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Journal of Medicinal Chemistry|May 2, 2003
Benzodiazepines as potent and selective bradykinin B1 antagonistsMichael R Wood, June J Kim, Wei Han, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic SteatohepatitisJan Best, Lars P Bechmann, Jan-Peter Sowa, et al.
Journal of Hepatology|April 17, 2020
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>Quentin M Anstee, Rebecca Darlay, Simon Cockell, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi studyJeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
The Lancet. Gastroenterology & Hepatology|December 9, 2023
Implementation of a liver health check in people with type 2 diabetesKushala W M Abeysekera, Luca Valenti, Zobair Younossi, et al.
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Journal of Hepatology|November 5, 2025
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLDMathias Jachs, Paul Thöne, Aitor Odriozola, et al.
Pageof 40

Showing results (341-350 of 392) with videos related to

Sort By:
Pageof 40
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Journal of Medicinal Chemistry|May 2, 2003
Benzodiazepines as potent and selective bradykinin B1 antagonistsMichael R Wood, June J Kim, Wei Han, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic SteatohepatitisJan Best, Lars P Bechmann, Jan-Peter Sowa, et al.
Journal of Hepatology|April 17, 2020
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>Quentin M Anstee, Rebecca Darlay, Simon Cockell, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi studyJeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
The Lancet. Gastroenterology & Hepatology|December 9, 2023
Implementation of a liver health check in people with type 2 diabetesKushala W M Abeysekera, Luca Valenti, Zobair Younossi, et al.
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Journal of Hepatology|November 5, 2025
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLDMathias Jachs, Paul Thöne, Aitor Odriozola, et al.
Pageof 40